Lexicon Pharmaceuticals Valuation Multiples

Lexicon Pharmaceuticals Overview

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Founded

1995

HQ

Employees

103

Website

lexpharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $46M

EBITDA: ($53M)

EV

$592M

Valuation Multiples

Multiples.vc

Start free trial

Lexicon Pharmaceuticals Financials

Lexicon Pharmaceuticals reported last 12-month revenue of $46M and negative EBITDA of ($53M).

In the same LTM period, Lexicon Pharmaceuticals generated $46M in gross profit, ($53M) in EBITDA losses, and had net loss of ($55M).

Lexicon Pharmaceuticals P&L

In the most recent fiscal year, Lexicon Pharmaceuticals reported revenue of $50M and EBITDA of ($41M).

Lexicon Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Lexicon Pharmaceuticals Stock Performance

Lexicon Pharmaceuticals has current market cap of $650M, and enterprise value of $592M.

Lexicon Pharmaceuticals' stock price is $1.56.

Lexicon Pharmaceuticals Valuation Multiples

Lexicon Pharmaceuticals trades at 12.8x EV/Revenue multiple, and (11.1x) EV/EBITDA.

Lexicon Pharmaceuticals Financial Valuation Multiples

As of March 21, 2026, Lexicon Pharmaceuticals has market cap of $650M and EV of $592M.

Equity research analysts estimate Lexicon Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Lexicon Pharmaceuticals has a P/E ratio of (11.8x).

Lexicon Pharmaceuticals Margins & Growth Rates

Lexicon Pharmaceuticals' revenue in the last 12 month declined by (34%).

Lexicon Pharmaceuticals' revenue per employee in the last FY averaged $0.5M.

Lexicon Pharmaceuticals' rule of 40 is (149%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Lexicon Pharmaceuticals' rule of X is (199%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Lexicon Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Lexicon Pharmaceuticals M&A Activity

Lexicon Pharmaceuticals acquired XXX companies to date.

Last acquisition by Lexicon Pharmaceuticals was on XXXXXXXX, XXXXX. Lexicon Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Lexicon Pharmaceuticals Investment Activity

Lexicon Pharmaceuticals invested in XXX companies to date.

Lexicon Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Lexicon Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).